Synergy Pharmaceuticals Inc


Analyst Cuts Price Target on Synergy Pharmaceuticals Inc (SGYP); All Chips Are Riding on Trulance Uptake

Though Cantor’s William Tanner keeps SGYP’s capital needs and prospective dilution in mind, he is confident on Trulance’s uptake in the market.

Synergy Pharmaceuticals Inc (SGYP): Trulance Picking Up Steam

H.C. Wainwright’s Ram Selvaraju is pleased to see Synergy’s momentum following a robust fourth quarter print and debt restructuring strides forward.

Synergy Pharmaceuticals Inc (SGYP): Analysts Weigh in on Trulance’s 4Q Beat

Investors snapped up Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares a day after the drug maker released …

Synergy Pharmaceuticals Inc (SGYP) Has Encouraging Sustainability Through 2019 Thanks to $300 Million Debt Financing

Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.

Analysts Shine More Light on These 2 Biotech Stocks: Synergy Pharmaceuticals Inc and Gilead Sciences, Inc.

Synergy Still Showcases Promising Commercial Trajectory in CIC Rodman & Renshaw analyst Ram Selvaraju still …

Synergy Pharmaceuticals Inc (SGYP) Trulance Market Adoption Pattern Looks Positive: Canaccord

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is on the downward spiral today, to the harsh, discordant …